Boehringer Ingelheim Reports Results of Cyltezo (biosimilar, adalimumab) in P-III VOLTAIRE-X Study for Moderate-to-Severe Chronic Plaque Psoriasis

 Boehringer Ingelheim Reports Results of Cyltezo (biosimilar, adalimumab) in P-III VOLTAIRE-X Study for Moderate-to-Severe Chronic Plaque Psoriasis

Shots:

  • The P-III VOLTAIRE-X interchangeability study involves assessing the PK similarity, efficacy, immunogenicity, and safety profiles between patients with mod. to-sev. chronic PsO receiving Humira (40mg/0.8mL) continuously vs those who switched several times b/w Cyltezo and Humira
  • Results: @32wks. the study met its 1EPs, supporting Cyltezo’s application as an interchangeable biosimilar to the reference product
  • The study showed that switching b/w Cyltezo (adalimumab-adbm) and Humira resulted in similar PK, efficacy, immunogenicity, and safety. The company has submitted sBLA for Cyltezo for designation as an interchangeable biosimilar to Humira with an anticipated PDUFA date in Q4’21

Click here to­ read full press release/ article | Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post